Purine synthesis machinery and nucleic acids

The purine synthesis machinery and nucleic acids encompass the complex metabolic pathways and macromolecular structures essential for cellular genetic integrity and energy transfer. This system includes the de novo purine biosynthetic pathway, which assembles the purine ring on a ribose-5-phosphate backbone, and the salvage pathway, which recycles free purine bases (StatPearls, 2023). These processes are fundamental for providing the nucleotide triphosphates (ATP and GTP) necessary for genetic coding, energy transfer, and signal transduction (NCBI, 2022). In medicine, this machinery is targeted by antimetabolite drugs that either inhibit rate-limiting enzymes, such as inosine monophosphate dehydrogenase (IMPDH), or serve as structural analogs that are incorporated into nucleic acids to cause chain termination or lethal mutations (PubMed, 2021). Such interventions are widely used to treat malignancies and autoimmune disorders by selectively impairing the proliferation of rapidly dividing cells. However, because these pathways are also active in healthy tissues like bone marrow, therapeutic use is often limited by toxicities such as leukopenia and anemia.

Other names

Purine metabolismDe novo purine biosynthesisPurine salvage pathwayNucleotide synthesis pathwayDNA and RNA synthesis

Inhibition of key enzymes in the purine de novo or salvage pathways (e.g., IMPDH, DHFR) leads to the depletion of essential nucleotide pools, while purine analogs act as antimetabolites that incorporate into DNA and RNA to disrupt synthesis and induce apoptosis.